Flumazenil: The Essential Antidote for Benzodiazepine Overdose

Benzodiazepines are a class of medications widely prescribed for anxiety, insomnia, and seizures. While generally safe when used as directed, benzodiazepine overdose can lead to significant respiratory depression, coma, and even death. In such emergencies, flumazenil stands as a critical antidote, capable of reversing the sedative effects of these drugs. This article delves into the crucial aspects of flumazenil, providing a comprehensive guide for healthcare professionals on its use as an antidote for benzodiazepine toxicity.

This resource aims to empower clinicians with the knowledge to confidently and effectively utilize flumazenil. By understanding its mechanisms, indications, administration, and potential risks, healthcare providers can optimize patient outcomes in benzodiazepine overdose situations and ensure the safe reversal of benzodiazepine-induced sedation in various clinical settings. A thorough understanding of flumazenil’s role is paramount in modern emergency medicine and critical care.

Objectives:

• Recognize clinical scenarios where flumazenil administration is necessary for benzodiazepine overdose reversal.
• Distinguish between approved and off-label uses of flumazenil as a benzodiazepine antidote.
• Assess patients for potential benzodiazepine withdrawal symptoms and adverse reactions following flumazenil administration.
• Foster effective interprofessional collaboration to enhance treatment strategies for patients who require flumazenil.

Access free multiple choice questions on this topic.

Indications for Flumazenil: A Benzodiazepine Antagonist

Flumazenil is primarily recognized as a benzodiazepine antagonist, serving as a vital antidote to counteract the effects of benzodiazepines.

FDA-Approved Uses of Flumazenil

• Benzodiazepine Overdose Treatment: Flumazenil is FDA-approved for the complete or partial reversal of the sedative effects of benzodiazepines in overdose situations. This indication spans both adult and pediatric populations and is categorized as follows:

  • Adult, Category B, Class IIa
  • Pediatric, Category C, Class IIb

• Reversal of Postoperative Sedation from Benzodiazepine Anesthetics: Flumazenil is also indicated for reversing sedation induced by benzodiazepine anesthetics following surgical procedures in both adults and children:

  • Adult, Category B, Class IIa
  • Pediatric, Category B, Class IIa

• Reversal of Sedation in Conscious Sedation and General Anesthesia: Flumazenil is explicitly indicated for the complete or partial reversal of benzodiazepine-induced sedation in conscious sedation and general anesthesia. Its use can expedite recovery from sedation after minor surgical interventions, potentially shortening post-operative monitoring and facilitating earlier patient discharge. This is particularly beneficial in outpatient settings and procedures where rapid recovery is desired.

• Management of Benzodiazepine Overdose Coma: Flumazenil is a valuable tool in managing and treating benzodiazepine overdose in adults, particularly in reversing coma resulting from benzodiazepine intoxication. It is generally more effective in reversing sedation or coma specifically caused by benzodiazepines compared to cases of multiple drug overdoses where benzodiazepines might be just one component of the intoxication.

Off-Label Applications of Flumazenil

While FDA-approved for specific benzodiazepine-related scenarios, flumazenil has also found utility in off-label settings, demonstrating its potential in a broader range of clinical situations. These off-label uses should be approached with caution and based on clinical judgment:

• Alcohol Withdrawal Syndrome: Flumazenil has been explored in managing alcohol withdrawal syndrome, although its use in this context is controversial and not widely adopted. The rationale is based on the GABAergic mechanisms shared by benzodiazepines and alcohol.

• Baclofen Reversal: Flumazenil has been reported to reverse the effects of baclofen overdose. Baclofen, a GABA-B receptor agonist, shares some pharmacological similarities with benzodiazepines, making flumazenil a potential antidote in baclofen toxicity.

• Idiopathic Recurring Stupor: In rare cases of idiopathic recurring stupor, where the cause of recurrent episodes of unresponsiveness is unclear, flumazenil has been used diagnostically and therapeutically, particularly if benzodiazepine receptor involvement is suspected.

• Cannabis Toxicity: Emerging research suggests a potential role for flumazenil in managing severe cannabis toxicity, especially in cases presenting with significant central nervous system depression. However, this is not a standard treatment and requires further investigation.

• Hepatic Encephalopathy: Flumazenil has been investigated for the management of hepatic encephalopathy, a condition associated with altered mental status in liver disease. While it may offer transient improvement in overt hepatic encephalopathy, it is not shown to improve long-term survival and is not a primary treatment.

• Benzodiazepine Detoxification: In specific protocols for benzodiazepine detoxification, particularly in managing paradoxical reactions or severe withdrawal symptoms, continuous infusion of flumazenil has been explored as a supportive measure, although this is not a common practice and requires careful monitoring.

Mechanism of Action: How Flumazenil Works as a Benzodiazepine Antidote

Flumazenil functions as a competitive benzodiazepine antagonist. It exerts its antidote effect by competitively inhibiting the activity of benzodiazepines and non-benzodiazepine substances that act at the benzodiazepine receptor site on the GABA_A/benzodiazepine receptor complex. Essentially, flumazenil competes with benzodiazepines for binding to these receptors, effectively reversing the effects of benzodiazepines. It can displace benzodiazepines already bound to these receptors.

Intravenously administered flumazenil effectively antagonizes the sedative effects, memory impairment, and psychomotor deficits induced by benzodiazepines. This reversal is rapid and predictable, making it invaluable in emergency situations and post-anesthesia recovery.

Pharmacokinetics of Flumazenil

Understanding flumazenil’s pharmacokinetic properties is crucial for appropriate dosing and anticipating its duration of action:

Absorption: Following intravenous (IV) administration, flumazenil exhibits a rapid onset of action, typically within 1 to 2 minutes. A significant portion of the therapeutic response, around 80%, is observed within the first 3 minutes post-administration. The peak effect is usually reached within 6 to 10 minutes.

Distribution: Flumazenil distributes extensively into the extracellular space. Its initial apparent volume of distribution is approximately 0.5 L/kg, increasing to a steady-state plasma concentration volume of 0.9 to 1.1 L/kg. Plasma protein binding is moderate, around 50%, with albumin contributing to about two-thirds of this binding.

Metabolism: Flumazenil undergoes near-complete metabolism in the liver. The metabolites are primarily inactive. Only minor fractions (less than 1%) of the parent drug are excreted unchanged in the urine.

Elimination: Elimination of radiolabeled flumazenil is essentially complete within 72 hours, with the majority (90% to 95%) of radioactivity excreted in urine and a smaller fraction (5% to 10%) in feces. Hepatic metabolism is the primary route of clearance. In healthy volunteers, total clearance rates range from 0.8 to 1.0 L/hr/kg. The elimination half-life of flumazenil is approximately 54 minutes, with a variability of about 21% (ranging from 41 to 79 minutes). This relatively short half-life is clinically significant as it means re-sedation may occur within 1 to 2 hours after administration, especially with longer-acting benzodiazepines, potentially necessitating repeat doses.

Administration of Flumazenil: Dosage and Guidelines

Proper administration of flumazenil is critical to ensure its effectiveness as a benzodiazepine antidote and to minimize potential adverse effects.

Available Dosage Forms and Strengths

Flumazenil is available as an injectable solution for intravenous (IV) infusion. The standard concentration is 0.1 mg/mL of flumazenil. Once drawn into a syringe or mixed with compatible intravenous solutions like D5W (5% dextrose in water), Lactated Ringer’s (LR), or Normal Saline (NS), the solution is stable for 24 hours. Administration is typically via free-flowing IV infusion into a large vein or through a series of small, titrated injections.

Adult Dosage Guidelines

FDA Dosage for Benzodiazepine Overdose Management:

• Initial Dose: Administer 0.2 mg IV over 30 seconds.
• Repeat Doses: If the desired level of consciousness is not achieved after 30 seconds, administer an additional 0.3 mg IV over 30 seconds.
• Subsequent Doses: Repeat doses of 0.5 mg IV over 30 seconds at 1-minute intervals, up to a maximum cumulative dose of 3 mg.
• Partial Response: Patients exhibiting a partial response after 3 mg may require further slow titration, up to a total dosage of 5 mg.
• No Response: If no significant response is observed after a cumulative dose of 5 mg, it is highly likely that benzodiazepines are not the primary cause of sedation, and further flumazenil administration is unlikely to be effective.
• Re-sedation: In cases of recurrent sedation, repeat doses may be administered at 20-minute intervals, not exceeding 1 mg (0.5 mg/minute) per dose or a total of 3 mg per hour.

FDA Dosage for Benzodiazepine Reversal in Conscious Sedation or General Anesthesia:

• Initial Dose: Administer 0.2 mg IV over 15 seconds.
• Repeat Doses: If the desired level of consciousness is not achieved after 45 seconds, repeat 0.2 mg IV at 1-minute intervals, up to a maximum of four additional doses if needed.
• Maximum Cumulative Dose: The maximum total cumulative dose in this setting is 1 mg.
• Re-sedation: For recurrent sedation, repeat doses may be given at 20-minute intervals, not exceeding 0.2 mg/minute per dose or a total of 3 mg per hour.

Specific Patient Populations and Dosage Adjustments

• Hepatic Impairment: Dosage adjustment is essential for patients with hepatic insufficiency, as flumazenil is primarily metabolized by the liver. While the initial dose for benzodiazepine reversal remains the same, subsequent doses should be reduced in dosage or frequency to avoid accumulation and prolonged effects.

• Renal Impairment: According to FDA labeling, no specific dosage adjustments are typically required for patients with renal impairment (creatinine clearance >10 mL/min). However, clinical judgment should always guide dosing, particularly in severe renal dysfunction.

• Pregnancy Considerations: Flumazenil is categorized as Pregnancy Category C. While supportive measures are usually effective in benzodiazepine toxicity during pregnancy, a case report suggests flumazenil’s potential to reverse fetal cardiac rhythm abnormalities induced by maternal diazepam overdose. Use during pregnancy should be considered when the potential benefits outweigh the risks to the fetus.

• Breastfeeding Considerations: Caution is advised when administering flumazenil to breastfeeding women, as its presence in human milk is not definitively established. Limited data exists on its use during breastfeeding. If flumazenil is necessary for the mother, breastfeeding can potentially continue. Given the drug’s half-life of approximately 54 minutes, abstaining from breastfeeding for 4 to 5 hours post-administration may help minimize infant exposure.

• Pediatric Patients: Flumazenil is FDA-approved for benzodiazepine reversal in conscious sedation or general anesthesia in pediatric patients.

  • Initial Dose: 0.01 mg/kg administered IV over 15 seconds (up to a maximum dose of 0.2 mg).
  • Repeat Doses: If the desired level of consciousness is not achieved after 45 seconds, repeat 0.01 mg/kg (up to 0.2 mg) at 1-minute intervals as needed, up to a maximum of four additional doses.
  • Maximum Cumulative Dose: The maximum total cumulative dose is 1 mg or 0.05 mg/kg, whichever is lower. Clinical trials have reported a mean total dose of 0.65 mg (range: 0.08 to 1 mg) in pediatric populations.

• Older Patients: Studies in older patients (over 65 years, including those over 80) indicate that while benzodiazepine doses for sedation induction should be reduced in this population, the standard flumazenil dosage is generally effective for reversal in older adults. However, due to age-related pharmacokinetic and pharmacodynamic changes, careful titration and monitoring are recommended.

Adverse Effects of Flumazenil: Risks and Considerations

While flumazenil is a valuable antidote, it is not without potential adverse effects. Understanding these risks is crucial for safe and appropriate use.

Serious Adverse Events

• Seizures: Perhaps the most concerning adverse effect, seizures are a recognized risk, particularly in patients with benzodiazepine dependence or those with a history of seizure disorders. Flumazenil-induced seizures can be challenging to manage and may require larger doses of benzodiazepines for control.
• Arrhythmias: Cardiac arrhythmias, although less common, have been reported in association with flumazenil administration. Patients with pre-existing cardiac conditions may be at increased risk.
• Neurologic Effects: Beyond seizures, other serious neurologic effects can occur, including agitation, confusion, and rarely, status epilepticus.
• Sedation: Paradoxically, sedation can occur as an adverse effect of flumazenil in some individuals, especially if the benzodiazepine effect is not fully reversed or if re-sedation occurs.

Common Adverse Events

• Cardiovascular:
  • Bradycardia (slow heart rate)
  • Tachycardia (fast heart rate)
  • Hypertension (high blood pressure)
  • Chest pain
• Neurologic:
  • Confusion
  • Dizziness
  • Headache
  • Impaired cognition
  • Opisthotonus (muscle spasms causing arching of the back)
  • Shivering
  • Somnolence (drowsiness)
• Gastrointestinal:
  • Nausea
  • Vomiting
• Immunologic:
  • Injection site reaction (pain, redness, swelling)
• Ophthalmic:
  • Visual field defects
  • Diplopia (double vision)
  • Blurred vision
• Otic:
  • Transient hearing impairment
• Dermatologic:
  • Diaphoresis (excessive sweating)
  • Injection site pain
• Psychiatric:
  • Anxiety
  • Psychotic disorder
  • Agitation
  • Panic attack, especially in patients with a history of panic disorder

Drug-Drug Interactions and Flumazenil

• Tricyclic Antidepressants (TCAs): Extreme caution is necessary when using flumazenil in mixed drug overdoses, particularly those involving tricyclic antidepressants like amitriptyline, nortriptyline, clomipramine, and imipramine. The risk of seizures is significantly increased in this setting. In severe TCA toxicity characterized by dysrhythmias, anticholinergic signs, and cardiovascular collapse, flumazenil is generally contraindicated. Supportive care is prioritized until TCA toxicity symptoms subside.

• Vecuronium: A practical concern is the potential for medication errors due to visual similarity between vials of flumazenil and vecuronium (a neuromuscular blocker) after removing their colored caps. Both may be stored in procedural areas, increasing the risk of mix-up. Careful labeling and verification are essential.

Contraindications and Precautions for Flumazenil Use

Certain conditions and situations contraindicate or warrant caution when considering flumazenil administration.

Absolute Contraindications

• Hypersensitivity: Known hypersensitivity to flumazenil or benzodiazepines is an absolute contraindication.
• Benzodiazepine Use for Life-Threatening Conditions: Flumazenil is contraindicated if benzodiazepines are used to control life-threatening conditions such as increased intracranial pressure or status epilepticus. Reversing benzodiazepine effects in these situations could be detrimental.

Warnings and Precautions

• Panic Disorder: Flumazenil can provoke panic attacks in patients with a history of panic disorder due to the abrupt reversal of benzodiazepine effects.
• Benzodiazepine Dependence: Convulsions are a significant risk in patients with chronic benzodiazepine dependence who receive flumazenil. Abrupt withdrawal can precipitate seizures.
• Head Injury: Flumazenil may precipitate convulsions or alter cerebral blood flow in patients with head injuries, potentially worsening neurological outcomes.
• Epilepsy: Increased seizure risk exists in epileptic patients who have been on benzodiazepine treatment for a prolonged period. Flumazenil should be used with extreme caution in these individuals.
• Drug Dependency and Alcoholism: Caution is advised in patients with drug dependency or alcoholism due to the increased likelihood of benzodiazepine tolerance and dependence in these populations. The risk of withdrawal seizures is higher.
• Severe Lung Disease: Flumazenil should not be used as the primary treatment in patients with severe lung disease experiencing respiratory depression secondary to benzodiazepines. Addressing the underlying respiratory condition is paramount.
• Tricyclic Antidepressant Overdose: As mentioned, signs of tricyclic antidepressant overdose or mixed overdoses involving TCAs are a strong precaution against flumazenil use due to the heightened risk of seizures and cardiac complications.

US Box Warning: While the original article mentions a US Box Warning, it does not specify its content. Typically, Box Warnings highlight significant risks associated with a medication. For flumazenil, the Box Warning often emphasizes the risk of seizures, particularly in benzodiazepine-dependent patients, and the contraindication in patients who have used benzodiazepines to control seizures or increased intracranial pressure.

Monitoring Patients After Flumazenil Administration

Post-flumazenil monitoring is crucial to detect and manage potential complications, particularly re-sedation and withdrawal.

Essential Monitoring Parameters:

• Respiratory Depression: Continuous monitoring for respiratory depression is paramount, as the benzodiazepine effect may return, especially with longer-acting benzodiazepines.
• Benzodiazepine Withdrawal: Closely monitor for signs and symptoms of benzodiazepine withdrawal, such as anxiety, agitation, tremors, tachycardia, hypertension, and seizures. Withdrawal symptoms can be severe and potentially life-threatening, especially in dependent individuals.
• Residual Benzodiazepine Effects: Observe for other residual effects of benzodiazepines, such as cognitive impairment or psychomotor deficits, which may persist even after apparent reversal of sedation.

Duration of Monitoring:

• Patients should be monitored for at least 2 hours after flumazenil administration, and potentially longer, depending on the clinical context, the benzodiazepine involved (especially if long-acting), and the patient’s risk factors for re-sedation or withdrawal.

Management of Seizures:

• Be prepared to manage seizures that may occur secondary to flumazenil administration. Paradoxically, seizures induced by flumazenil may require larger doses of benzodiazepines for control.

Re-sedation Management:

• Monitor closely for the return of sedation, especially in patients who are tolerant to benzodiazepines or in cases of long-acting benzodiazepine overdose. Re-sedation is a recognized phenomenon due to flumazenil’s shorter half-life compared to many benzodiazepines.
• Re-sedation can be treated with repeat doses of flumazenil in adults, administered until the desired therapeutic effect is achieved. Continuous infusion of flumazenil has also been used in some cases of recurrent sedation or toxicity from long-acting benzodiazepines.

Flumazenil Toxicity and Overdose

While flumazenil is an antidote, overdose is rare but can occur. It is important to recognize the signs and management strategies for flumazenil toxicity.

Clinical Features of Flumazenil Overdose:

• Anxiety and Agitation: Paradoxical excitation, anxiety, and agitation can be prominent features of flumazenil overdose.
• Increased Muscle Tone and Hyperesthesia: Muscle rigidity and increased sensitivity to stimuli (hyperesthesia) may be observed.
• Seizures: In severe cases, seizures can occur as a manifestation of flumazenil toxicity itself.

Management of Flumazenil Toxicity:

• No Specific Antidote: Currently, there is no specific antidote for flumazenil toxicity.
• Symptomatic and Supportive Treatment: Management focuses on symptomatic and supportive care. This may include:
  • Managing agitation and anxiety with reassurance and potentially with medications (though benzodiazepines would be contraindicated given flumazenil’s mechanism).
  • Monitoring and supporting vital functions, including respiratory and cardiovascular systems.
  • Managing seizures with appropriate anticonvulsant medications (non-benzodiazepine if possible, or carefully titrated benzodiazepines if necessary).

Consultation Criteria:

• Consult a medical toxicologist or local poison control center for any patient with suspected severe adverse effects after receiving flumazenil, such as seizures, dysrhythmias, and hypotension. These experts can provide guidance on complex management strategies and risk assessment.

Enhancing Healthcare Team Outcomes in Benzodiazepine Overdose Management

In the context of the ongoing opioid and drug overdose epidemic, healthcare professionals must be proficient in using flumazenil as a benzodiazepine antidote. While initially hailed as a wonder drug, the understanding of flumazenil has evolved, recognizing both its benefits and potential risks.

Interprofessional Collaboration is Key:

• Clinicians (MDs, DOs, NPs, PAs): Prescribing clinicians must be aware of the indications, contraindications, and risks associated with flumazenil. They are responsible for assessing the patient, determining the need for flumazenil, and overseeing the overall management.
• Nurses: Nurses play a critical role in administering flumazenil, monitoring patients for therapeutic effects and adverse reactions (including re-sedation and withdrawal), and providing essential supportive care.
• Pharmacists: Hospital pharmacists ensure proper dosing of flumazenil and can provide valuable drug information to the team. They can also identify potential drug interactions and contraindications.
• Emergency Department and Critical Care Specialists: Flumazenil use is often initiated in the emergency department. Critical care consultation is vital in severe poisoning cases, particularly those with respiratory depression or hemodynamic instability.
• Medical Toxicologists: Medical toxicologist consultation is frequently needed, especially in cases of multiple-drug ingestions or complex presentations, to guide management decisions and risk stratification.

Education and Patient Safety:

• Patient Education: Nurses and pharmacists are crucial in educating patients and their families about benzodiazepines, their potential for addiction and physical dependence, and the importance of using them only as prescribed.
• Risk Awareness: All clinicians should be aware of the circumstances where flumazenil should be avoided, such as in patients with a history of seizures, head injury, or tricyclic antidepressant ingestion.
• Ideal Use Case: The ideal scenario for flumazenil use is in a benzodiazepine-naive individual who has overdosed on benzodiazepines alone. In such cases, the benefits often outweigh the risks.

Shifting Paradigms in Benzodiazepine Overdose Management:

• Supportive Care First: For isolated benzodiazepine overdoses, supportive management alone (monitoring airway, breathing, and circulation) is often sufficient, as benzodiazepine overdose alone rarely causes significant mortality.
• Flumazenil: Not Always Necessary: The use of flumazenil to manage benzodiazepine overdose is diminishing in some settings as evidence suggests it may sometimes cause more harm than good, particularly if used indiscriminately.
• Co-ingestion Risks: The primary concern in benzodiazepine overdose arises when there is co-ingestion of other substances, such as alcohol or other illicit drugs. In these complex cases, the role of flumazenil needs to be carefully considered.

By fostering a collaborative interprofessional team approach, healthcare providers can optimize the efficacy of flumazenil therapy while minimizing its potential risks, ultimately improving patient outcomes in benzodiazepine overdose scenarios. Continuous education and awareness of best practices are essential in this evolving field.

[Review Questions]

[References]

1.Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD011481. [PMC free article: PMC6513394] [PubMed: 29543325]
2.Zhu S, Noviello CM, Teng J, Walsh RM, Kim JJ, Hibbs RE. Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72. [PMC free article: PMC6220708] [PubMed: 29950725]
3.Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018: A Report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. Anesthesiology. 2018 Mar;128(3):437-479. [PubMed: 29334501]
4.Seelhammer TG, DeGraff EM, Behrens TJ, Robinson JC, Selleck KL, Schroeder DR, Sprung J, Weingarten TN. [The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes]. Braz J Anesthesiol. 2018 Jul-Aug;68(4):329-335. [PMC free article: PMC9391726] [PubMed: 29631877]
5.Wu Q, Xu F, Wang J, Jiang M. Comparison of Remimazolam-Flumazenil versus Propofol for Recovery from General Anesthesia: A Systematic Review and Meta-Analysis. J Clin Med. 2023 Nov 26;12(23) [PMC free article: PMC10707179] [PubMed: 38068368]
6.Nelson LS. Alcohol withdrawal and flumazenil: not for the faint of heart. J Med Toxicol. 2014 Jun;10(2):123-5. [PMC free article: PMC4057543] [PubMed: 24595919]
7.Franchitto N, Pelissier F, Lauque D, Simon N, Lançon C. Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol. 2014 Jan-Feb;49(1):79-83. [PubMed: 24226812]
8.Asthana V, Agrawal S, Goel D, Sharma JP. Idiopathic recurrent stupor mimicking status epilepticus. Singapore Med J. 2008 Oct;49(10):e276-7. [PubMed: 18946597]
9.Crippa JA, Derenusson GN, Chagas MH, Atakan Z, Martín-Santos R, Zuardi AW, Hallak JE. Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J. 2012 Jan 25;9:7. [PMC free article: PMC3294246] [PubMed: 22273390]
10.Reinert JP, Burnham K. Non-Lactulose Medication Therapies for the Management of Hepatic Encephalopathy: A Literature Review. J Pharm Pract. 2021 Dec;34(6):922-933. [PubMed: 32878558]
11.Benini A, Gottardo R, Chiamulera C, Bertoldi A, Zamboni L, Lugoboni F. Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification. Front Psychiatry. 2021;12:646038. [PMC free article: PMC8012511] [PubMed: 33815177]
12.An H, Godwin J. Flumazenil in benzodiazepine overdose. CMAJ. 2016 Dec 06;188(17-18):E537. [PMC free article: PMC5135539] [PubMed: 27920113]
13.Amrein R, Hetzel W, Hartmann D, Lorscheid T. Clinical pharmacology of flumazenil. Eur J Anaesthesiol Suppl. 1988;2:65-80. [PubMed: 2842143]
14.van Rij CM, Huitema AD, Swart EL, Greuter HN, Lammertsma AA, van Loenen AC, Franssen EJ. Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. Br J Clin Pharmacol. 2005 Nov;60(5):477-85. [PMC free article: PMC1884950] [PubMed: 16236037]
15.Kiyama S. Re-sedation after a large dose of flumazenil. J Anesth. 2023 Feb;37(1):161. [PubMed: 36242628]
16.Parthvi R, Mehra S. Flumazenil for Mixed Drug Overdose. Am J Ther. 2018 Nov/Dec;25(6):e676-e677. [PubMed: 28708699]
17.Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35. [PubMed: 25042402]
18.Janssen U, Walker S, Maier K, von Gaisberg U, Klotz U. Flumazenil disposition and elimination in cirrhosis. Clin Pharmacol Ther. 1989 Sep;46(3):317-23. [PubMed: 2505960]
19.Zelner I, Matlow J, Hutson JR, Wax P, Koren G, Brent J, Finkelstein Y., Toxicology Investigators Consortium (ToxIC). Acute Poisoning During Pregnancy: Observations from the Toxicology Investigators Consortium. J Med Toxicol. 2015 Sep;11(3):301-8. [PMC free article: PMC4547956] [PubMed: 25783189]
20.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Aug 15, 2023. Flumazenil. [PubMed: 37603673]
21.Penninga EI, Graudal N, Ladekarl MB, Jürgens G. Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication–A Systematic Review with Meta-Analyses of Randomised Trials. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):37-44. [PubMed: 26096314]
22.Wong M. Reversal Agents in Sedation and Anesthesia Practice for Dentistry. Anesth Prog. 2022 Apr 01;69(1):49-58. [PMC free article: PMC8985463] [PubMed: 35377935]
23.Veiraiah A, Dyas J, Cooper G, Routledge PA, Thompson JP. Flumazenil use in benzodiazepine overdose in the UK: a retrospective survey of NPIS data. Emerg Med J. 2012 Jul;29(7):565-9. [PubMed: 21785147]
24.Grissinger M. Paralyzed by Mistakes – Reassess the Safety of Neuromuscular Blockers in Your Facility. P T. 2019 Mar;44(3):91-107. [PMC free article: PMC6385733] [PubMed: 30828226]
25.Woolf AD, Erdman AR, Nelson LS, Caravati EM, Cobaugh DJ, Booze LL, Wax PM, Manoguerra AS, Scharman EJ, Olson KR, Chyka PA, Christianson G, Troutman WG. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(3):203-33. [PubMed: 17453872]
26.Seger DL. Flumazenil–treatment or toxin. J Toxicol Clin Toxicol. 2004;42(2):209-16. [PubMed: 15214628]
27.Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother. 1994 Dec;28(12):1347-9. [PubMed: 7696723]
28.Sivilotti ML. Flumazenil, naloxone and the ‘coma cocktail’. Br J Clin Pharmacol. 2016 Mar;81(3):428-36. [PMC free article: PMC4767210] [PubMed: 26469689]
29.Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS, Hoyte CO, Mazer-Amirshahi ME, Stolbach A, St-Onge M, Thompson TM, Wang GS, Hoover AV, Drennan IR., American Heart Association. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023 Oct 17;148(16):e149-e184. [PubMed: 37721023]
30.Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther. 1992 Mar-Apr;14(2):292-305. [PubMed: 1611650]
31.Rousseau-Blass F, Cribb AE, Beaudry F, Pang DS. A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). J Am Assoc Lab Anim Sci. 2021 May 01;60(3):319-328. [PMC free article: PMC8145127] [PubMed: 33673881]
32.Maxa JL, Ogu CC, Adeeko MA, Swaner TG. Continuous-infusion flumazenil in the management of chlordiazepoxide toxicity. Pharmacotherapy. 2003 Nov;23(11):1513-6. [PubMed: 14620397]
33.Wallace IR, Campbell EC, Trimble M. Use of a flumazenil infusion to treat chlordiazepoxide toxicity. Acute Med. 2017;16(1):30-34. [PubMed: 28424803]
34.Vukcević NP, Ercegović GV, Segrt Z, Djordjević S, Stosić JJ. Benzodiazepine poisoning in elderly. Vojnosanit Pregl. 2016 Mar;73(3):234-8. [PubMed: 27295906]
35.Kreshak AA, Cantrell FL, Clark RF, Tomaszewski CA. A poison center’s ten-year experience with flumazenil administration to acutely poisoned adults. J Emerg Med. 2012 Oct;43(4):677-82. [PubMed: 22766408]
36.Tamburin S, Faccini M, Casari R, Federico A, Morbioli L, Franchini E, Bongiovanni LG, Lugoboni F. Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. J Psychopharmacol. 2017 Oct;31(10):1369-1373. [PubMed: 28613124]
37.Tae CH, Kang KJ, Min BH, Ahn JH, Kim S, Lee JH, Rhee PL, Kim JJ. Paradoxical reaction to midazolam in patients undergoing endoscopy under sedation: Incidence, risk factors and the effect of flumazenil. Dig Liver Dis. 2014 Aug;46(8):710-5. [PubMed: 24893689]
38.Isbister GK, O’Regan L, Sibbritt D, Whyte IM. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol. 2004 Jul;58(1):88-95. [PMC free article: PMC1884537] [PubMed: 15206998]